Lexeo Therapeutics (LXEO) Total Current Liabilities (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Total Current Liabilities data on file, last reported at $14.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 53.97% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $14.2 million (down 53.97% YoY), and the FY2025 full-year result was $16.8 million, down 26.43% from the prior year.
• Total Current Liabilities slipped to $14.2 million in Q1 2026, from $16.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.6 million in Q2 2025 to a low of $14.2 million in Q1 2026.
• A 5-year average of $21.3 million and a median of $20.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 67.36% in 2025 and sank 53.97% in 2026, its largest moves.
• Tracing LXEO's Total Current Liabilities over 5 years: stood at $14.3 million in 2022, then grew by 20.14% to $17.2 million in 2023, then soared by 32.53% to $22.8 million in 2024, then retreated by 26.43% to $16.8 million in 2025, then slipped by 15.58% to $14.2 million in 2026.
• Business Quant data shows LXEO's Total Current Liabilities at $14.2 million in Q1 2026, $16.8 million in Q4 2025, and $17.3 million in Q3 2025.